Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
OTLK Stock Summary
Top 10 Correlated ETFs
OTLK
In the News
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy
Oncobiologics (OTLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
7 of the Best Speculative Stocks You Can Snag for Less Than $1
I'm about to drop a truth bomb about speculative stocks under $1. Back when I was a freshman in college, the on-campus security officer had this to say: “Tijuana?
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.
Best Penny Stocks To Buy Today? 3 To Watch This Week
Penny stocks, or “stocks under $5,” tend to occupy volatile territory with occasional meteoric runs. While savvy short-term traders eagerly scan for these explosive upside trades, penny stocks remain extremely high-risk.
Invest In Penny Stocks? Is It Worth It & 4 To Watch Now
If you're looking for penny stocks to invest in right now, you've got your work cut out for you. That's because the initial strategy when approaching cheap stocks is to trade them in the short term instead of holding them forever.
3 Penny Stocks To Buy According To Analysts, Targets Up To 365%
Penny stocks, defined as stocks trading under $5 per share, present traders and investors with opportunities for explosive returns. However, the penny stock territory also comes loaded with substantial risks.
5 Most Active Penny Stocks Today & Why They're Moving Now
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.
Outlook Therapeutics® to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference
Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET
Best Penny Stocks Under $1? 4 To Watch This Week
What are the best penny stocks under $1? If you saw this headline, that's probably a question you have heading into the second half of the week.
OTLK Financial details
OTLK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-09-30
Metric | History | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.45 | 0 | 0 | 0 | 0 | |
Net income per share | -1.9 | -0.41 | -0.35 | -0.31 | -0.24 | |
Operating cash flow per share | -1.77 | -0.37 | -0.36 | -0.27 | -0.17 | |
Free cash flow per share | -1.8 | -0.37 | -0.36 | -0.27 | -0.17 | |
Cash per share | 0.44 | 0.15 | 0.09 | 0.08 | 0.09 | |
Book value per share | -0.59 | 0.03 | 0.03 | 0.04 | -0.06 | |
Tangible book value per share | -0.59 | 0.03 | 0.03 | 0.04 | -0.06 | |
Share holders equity per share | -0.59 | 0.03 | 0.03 | 0.04 | -0.06 | |
Interest debt per share | 1.01 | 0.12 | 0.08 | 0.06 | 0.15 | |
Market cap | 542.12M | 1.23B | 6.63B | 5.17B | 1.11B | |
Enterprise value | 549.05M | 1.23B | 6.62B | 5.17B | 1.12B | |
P/E ratio | -15.7 | -34.91 | -124.64 | -78.34 | -18.75 | |
Price to sales ratio | 66.55 | 0 | 0 | 0 | 0 | |
POCF ratio | -16.79 | -38.7 | -122.13 | -91.31 | -25.73 | |
PFCF ratio | -16.56 | -38.7 | -122.13 | -91.31 | -25.73 | |
P/B Ratio | -50.34 | 435.33 | 1.44K | 592.31 | -76.59 | |
PTB ratio | -50.34 | 435.33 | 1.44K | 592.31 | -76.59 | |
EV to sales | 67.4 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -25.34 | -33.78 | -127.93 | -82.15 | -21.25 | |
EV to operating cash flow | -17 | -38.58 | -122.09 | -91.19 | -26.01 | |
EV to free cash flow | -16.78 | -38.58 | -122.09 | -91.19 | -26.01 | |
Earnings yield | -0.06 | -0.03 | -0.01 | -0.01 | -0.05 | |
Free cash flow yield | -0.06 | -0.03 | -0.01 | -0.01 | -0.04 | |
Debt to equity | -1.39 | 3.11 | 2.58 | 1.25 | -2.46 | |
Debt to assets | 0.87 | 0.45 | 0.52 | 0.38 | 1.1 | |
Net debt to EBITDA | -0.32 | 0.1 | 0.05 | 0.1 | -0.23 | |
Current ratio | 0.67 | 1.13 | 3.19 | 1.39 | 0.66 | |
Interest coverage | -10.47 | -20.98 | -55.26 | -42.4 | -34.06 | |
Income quality | 0.94 | 0.9 | 1.02 | 0.86 | 0.73 | |
Dividend Yield | 1.15K | 135.04 | 0 | 0 | 0 | |
Payout ratio | -18.1K | -4.71K | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.15 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 2.92 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.05 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.13 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.16 | 0 | 0 | 0 | 0 | |
Graham number | 5.03 | 0.55 | 0.49 | 0.54 | 0.55 | |
ROIC | -4.27 | -2.13 | -3.11 | -3.2 | -2.52 | |
Return on tangible assets | -2.01 | -1.79 | -2.33 | -2.32 | -1.83 | |
Graham Net | -1.09 | -0.05 | -0.02 | -0.01 | -0.09 | |
Working capital | -6.79M | 2.05M | 14.76M | 7.79M | -15.75M | |
Tangible asset value | -10.77M | 2.83M | 4.61M | 8.74M | -14.44M | |
Net current asset value | -14.4M | 1.04M | 3.3M | 7.73M | -15.76M | |
Invested capital | -1.39 | 3.11 | 2.58 | 1.25 | -2.46 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 2.94M | 2.34M | 2.3M | 2.84M | 5.03M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 34.93K | 1.58K | 3.06K | 6.23K | 54.31K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.01 | 0.23 | 0.12 | 0.06 | 0.01 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 3.21 | -12.47 | -11.54 | -7.56 | 4.09 | |
Capex per share | -0.02 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q1
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.1 | -0.03 | -0.08 | -0.05 | -0.04 | |
Operating cash flow per share | -0.04 | -0.03 | -0.05 | -0.05 | -0.05 | |
Free cash flow per share | -0.04 | -0.03 | -0.05 | -0.05 | -0.05 | |
Cash per share | 0.23 | 0.17 | 0.13 | 0.09 | 0.04 | |
Book value per share | 0.07 | 0.04 | -0.02 | -0.06 | -0.09 | |
Tangible book value per share | 0.07 | 0.04 | -0.02 | -0.06 | -0.09 | |
Share holders equity per share | 0.07 | 0.04 | -0.02 | -0.06 | -0.09 | |
Interest debt per share | 0.15 | -731.54 | -1.54K | 8.57K | -724.82 | |
Market cap | 4.91B | 5.6B | 8.94B | 1.11B | 2.05B | |
Enterprise value | 4.89B | 5.58B | 8.94B | 1.12B | 2.08B | |
P/E ratio | -56.75 | -210.22 | -108.1 | -21.28 | -45.87 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -551.84 | -689.54 | -676.4 | -86.79 | -157.37 | |
PFCF ratio | -551.84 | -689.54 | -676.4 | -86.79 | -157.37 | |
P/B Ratio | 311.7 | 533.5 | -1.62K | -76.59 | -84.25 | |
PTB ratio | 311.7 | 533.5 | -1.62K | -76.59 | -84.25 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -312.24 | -814.64 | -493.16 | -66.72 | -202.8 | |
EV to operating cash flow | -549.54 | -688.09 | -676.48 | -87.74 | -159.38 | |
EV to free cash flow | -549.54 | -688.09 | -676.48 | -87.74 | -159.38 | |
Earnings yield | 0 | 0 | 0 | -0.01 | -0.01 | |
Free cash flow yield | 0 | 0 | 0 | -0.01 | -0.01 | |
Debt to equity | 2.02 | 3.04 | -6.31 | -2.46 | -1.5 | |
Debt to assets | 0.51 | 0.59 | 0.78 | 1.1 | 1.69 | |
Net debt to EBITDA | 1.31 | 1.72 | -0.06 | -0.73 | -2.56 | |
Current ratio | 4.09 | 1.22 | 0.86 | 0.66 | 0.44 | |
Interest coverage | -6.41 | 0 | 0 | 0 | 0 | |
Income quality | 0.48 | 1.22 | 0.64 | 0.98 | 1.17 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.39 | 0.15 | 0.2 | 0.26 | 0.3 | |
ROIC | -0.38 | -0.16 | -0.61 | -127.61 | -0.84 | |
Return on tangible assets | -0.35 | -0.12 | -0.47 | -0.4 | -0.52 | |
Graham Net | 0.02 | 0 | -0.06 | -0.09 | -0.14 | |
Working capital | 46.59M | 9.52M | -6.91M | -15.75M | -25.58M | |
Tangible asset value | 15.76M | 10.49M | -5.5M | -14.44M | -24.34M | |
Net current asset value | 14.75M | 9.52M | -6.93M | -15.76M | -25.64M | |
Invested capital | 2.02 | 3.04 | -6.31 | -2.46 | -1.5 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3.83M | 3.89M | 4.34M | 5.81M | 5.03M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 34.82K | 29.61K | 40.65K | 52.75K | 11.11K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0.01 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.37 | -0.63 | 3.76 | 0.9 | 0.46 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
OTLK Frequently Asked Questions
What is Outlook Therapeutics, Inc. stock symbol ?
Outlook Therapeutics, Inc. is a US stock , located in Iselin of Nj and trading under the symbol OTLK
What is Outlook Therapeutics, Inc. stock quote today ?
Outlook Therapeutics, Inc. stock price is $11.94 today.
Is Outlook Therapeutics, Inc. stock public?
Yes, Outlook Therapeutics, Inc. is a publicly traded company.